Yearly Archives: 2025

A licensed version of Bisoprolol 1mg/ml oral solution sugar free was launched by Aspire Pharma Ltd in August 2025. However, at the same time an unlicensed version of Bisoprolol 5mg/5ml oral solution was listed in Part VIIIB of the Drug Tariff. According to the Drug Tariff rules, any generically written prescription for Bisoprolol 5mg/5ml (or [...]

The post Retrospective price adjustment for Bisoprolol 5mg/5ml oral solution for August 2025 appeared first on Community Pharmacy England.

Today (Wednesday 1st October 2025), several service and regulatory changes have come into effect, as well as today being the start date for several national services. Below is a summary of all these service developments and regulatory changes. Commencement of services From today, pharmacies registered to provide the services, can start to provide the Childhood [...]

The post Services and Regulatory changes coming into force today appeared first on Community Pharmacy England.

The 2024/25 annual report for Community Pharmacy England has been published, outlining what was another crucial year for the organisation and highlighting the breadth of work carried out on behalf of all community pharmacy owners. The year saw the first CPCF negotiations with the new Government, resulting in a positive step-change for the sector and [...]

The post Community Pharmacy England publishes 2024/25 Annual Report appeared first on Community Pharmacy England.

From 1 October 2025, generically written prescriptions for Tadalafil and Vardenafil preparations will no longer require the prescriber ‘SLS’ endorsement. However, the SLS endorsement requirements will continue to apply to the following branded versions – Cialis® and Levitra® which may only be ordered on NHS prescriptions issued for the treatment of erectile dysfunction in restricted circumstances. [...]

The post SLS endorsement requirements removed for Tadalafil and Vardenafil appeared first on Community Pharmacy England.

The NHS restrictions on prescribing of influenza antiviral treatments, Oseltamivir (Tamiflu®) and Zanamivir (Relenza®) have been relaxed to allow prescribing of these flu antivirals at any time of the year for patients in clinical at-risk groups as well as those who are at risk of severe illness and/or complications from flu if not treated. Previously, to [...]

The post Removal of prescribing restrictions on flu antivirals appeared first on Community Pharmacy England.